Drugs / Setanaxib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04327089 | Jun 2020 → Mar 2021 | — | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 1 | NCT03740217 | Dec 2018 → Feb 2019 | — | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06274489 | Nov 2023 → Jun 2025 | Alport syndrome | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT05323656 | Apr 2022 → Feb 2024 | head and neck squamous cell carcinoma | Calliditas Therapeutics AB | Completed | Missed primary |
| Phase 2 | NCT05014672 | Feb 2022 → May 2024 | primary biliary cholangitis | Calliditas Therapeutics AB | Completed | Met primary |
| Phase 2 | NCT03865927 | Sep 2020 → Nov 2024 | idiopathic pulmonary fibrosis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03226067 | Jun 2017 → Apr 2019 | primary biliary cholangitis | Calliditas Therapeutics AB | Completed | Missed primary |
| Phase 2 | NCT02010242 | Oct 2013 → Feb 2015 | diabetic kidney disease | Calliditas Therapeutics AB | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Setanaxib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04327089 ↗ |
| Known as | GKT-831 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303187 ↗ |
| Known as | GKT137831 | “Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4.” NCT06274489 ↗ |
| Action | Inhibit | “NOX1/4 inhibitor” NCT02010242 ↗ |
| Modality | Small molecule | “oral bioavailable small molecule that selectively inhibit NOX1 and NOX4” NCT03740217 ↗ |
| Route | Oral | “oral GKT137831 administered” NCT02010242 ↗ |
| Target | NOX1 | “GKT137831 is the first in class NOX1/4 inhibitor.” NCT02010242 ↗ |